Last reviewed · How we verify
Algorithm Treatment
At a glance
| Generic name | Algorithm Treatment |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events (NA)
- FAP-targeted PET/NIR in Lung Malignant Tumors
- Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure (NA)
- Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure (NA)
- Impact of First-trimester Preeclampsia Screening on Perinatal and Maternal Morbidity (RANSPRE) (NA)
- Prevent TB: Choice Architecture for TPT Delivery (NA)
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (NA)
- Three Different GHDT ( Goal Hemodynamic Directed Therapy) Strategies for Intraoperative Fluid Management Optimization During Major Abdominal Surgery: A Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Algorithm Treatment CI brief — competitive landscape report
- Algorithm Treatment updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI